Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Teva Pharmaceutical (TEVA) has shared an announcement.
Teva Pharmaceutical Industries Ltd. is undergoing a major executive shift as Mr. Eric Drapé steps down from his role as Executive Vice President, Global Operations, to be succeeded by Mr. Matthew Shields on June 3, 2024. Shields brings over 25 years of experience in biopharmaceuticals and animal health industries, having held significant positions at Merck Animal Health and Sanofi. His compensation package includes a base salary of $825,000, potential annual cash incentives, equity awards, and substantial severance benefits, positioning him as a key player in Teva’s future operations.
For an in-depth examination of TEVA stock, go to TipRanks’ Stock Analysis page.